{"id":42213,"date":"2018-04-26T21:03:14","date_gmt":"2018-04-26T19:03:14","guid":{"rendered":"https:\/\/newserver.fyb.de\/bravura-ipo-of-morphosys-in-the-usa-over-200-million-raised\/"},"modified":"2018-04-26T21:03:14","modified_gmt":"2018-04-26T19:03:14","slug":"bravura-ipo-of-morphosys-in-the-usa-over-200-million-raised","status":"publish","type":"post","link":"https:\/\/www.fyb.de\/en\/bravura-ipo-of-morphosys-in-the-usa-over-200-million-raised\/","title":{"rendered":"Bravura IPO of Morphosys in the USA \u2014 over $200 million raised"},"content":{"rendered":"<p>New York\/ Munich \u2014 <strong>Morpho\u00adsys<\/strong>, based in Munich, succee\u00added in achie\u00adving the largest IPO of a German biotech company on the Nasdaq in the USA to date and <strong>one of the largest share place\u00adments<\/strong> ever in <strong>the German biotech sector<\/strong>. The company\u2019s shares were previously only listed in Germany.<\/p>\n<p>With the fresh capi\u00adtal, Morpho\u00adsys is prepa\u00adring for the further expan\u00adsion of its clini\u00adcal rese\u00adarch and the possi\u00adble market launch of its first own product candi\u00addate in&nbsp;2020.<\/p>\n<p>The stock market proceeds will bring the company\u2019s capi\u00adtal reser\u00adves to around 450 million euros, a lot of money for the ambi\u00adtious projects.<\/p>\n<p>The expen\u00adsive drug rese\u00adarch and deve\u00adlo\u00adp\u00adment, which curr\u00adently still leads to losses on the balance sheet, was the driving force behind the US IPO. For 2018, the company is projec\u00adting around 100 million euros in rese\u00adarch costs and 110 to 120 million euros in opera\u00adting losses. But such numbers are not unknown to U.S. inves\u00adtors, nor are they a deal-brea\u00adker if the tech\u00adno\u00adlogy and over\u00adall stra\u00adtegy are judged to be of&nbsp;value.<\/p>\n<p>Morpho\u00adsys\u2019 stra\u00adte\u00adgic goal is to become a \u201cfully inte\u00adgra\u00adted commer\u00adcial biophar\u00admaceu\u00adti\u00adcal\u201d company with drugs deve\u00adlo\u00adped in-house. In this respect, the Munich-based company is in global compe\u00adti\u00adtion, espe\u00adci\u00adally with strong U.S. companies.<\/p>\n<p>Morpho\u00adsys\u2019 current hope is an anti\u00adbody compound called MOR208, which the company is test\u00ading in the final phase III trial against certain forms of blood cancer, so-called B\u2011cell lympho\u00admas. It could \u2014 if the promi\u00adsing data so far are further confirmed \u2014 enter the first appr\u00adoval proce\u00addu\u00adres next year and be laun\u00adched on the market in 2020. The U.S. Food and Drug Admi\u00adnis\u00adtra\u00adtion has gran\u00adted this drug candi\u00addate \u201cbreakth\u00adrough therapy\u201d status, which comes with expe\u00addi\u00adted consul\u00adta\u00adtion and review proce\u00addu\u00adres, among other bene\u00adfits. A further four proprie\u00adtary MOR product candi\u00adda\u00adtes are in earlier stages of clini\u00adcal development.<\/p>\n<p>In addi\u00adtion, clini\u00adcal trials with more than two dozen compounds based on Morpho\u00adsys\u2019 tech\u00adno\u00adlogy are curr\u00adently under\u00adway with part\u00adners from the phar\u00admaceu\u00adti\u00adcal indus\u00adtry. In the event of appr\u00adoval, the Munich-based company is entit\u00adled to royal\u00adties on these active ingre\u00addi\u00adents. A first product from these part\u00adner programs, the psoria\u00adsis drug Trem\u00adfya deve\u00adlo\u00adped by John\u00adson &amp; John\u00adson, has been appro\u00adved since 2017 \u2014 and is alre\u00adady gene\u00adra\u00adting initial reve\u00adnues for the Munich-based company. Nume\u00adrous other projects based on Morpho\u00adsys\u2019 subs\u00adtance libra\u00adries are in the earlier, precli\u00adni\u00adcal phase of rese\u00adarch: a total of around 100 anti\u00adbody projects.<\/p>\n<p>Thanks to this two-pron\u00adged stra\u00adtegy with the deve\u00adlo\u00adp\u00adment of proprie\u00adtary compounds and tech\u00adno\u00adlogy part\u00adner\u00adships, Morpho\u00adsys now has a rela\u00adtively broad base and is in prin\u00adci\u00adple not depen\u00addent on indi\u00advi\u00addual projects, and can focus on its own developments.<\/p>\n<p>The U.S. Nasdaq, at any rate, is deligh\u00adted with the weighty new addi\u00adtion, and its Presi\u00addent Nelson Griggs attests to the company from Plan\u00adegg near Munich: \u201cMorpho\u00adSys\u2019 rich expe\u00adri\u00adence in anti\u00adbody disco\u00advery and deve\u00adlo\u00adp\u00adment, coupled with its proprie\u00adtary tech\u00adno\u00adlo\u00adgies, makes it a leading company in the biophar\u00admaceu\u00adti\u00adcal indus\u00adtry. We are plea\u00adsed to welcome Morpho\u00adSys to the Nasdaq Stock Exch\u00adange and support the company\u2019s contin\u00adued success in impro\u00adving the lives of pati\u00adents with serious diseases.\u201d<\/p>\n<p>Morpho\u00adSys\u2019s common shares are listed on the Frank\u00adfurt Stock Exch\u00adange under the symbol \u201cMOR\u201d. The ADSs are listed on the Nasdaq Global Market under the symbol \u201cMOR.\u201d<\/p>\n<p>Gold\u00adman Sachs &amp; Co. LLC, J.P. Morgan Secu\u00adri\u00adties LLC and Leer\u00adink Part\u00adners LLC acted as lead book-running mana\u00adgers for the offe\u00adring; Beren\u00adberg Capi\u00adtal Markets, LLC and JMP Secu\u00adri\u00adties LLC acted as co-mana\u00adgers for the ADS offering.<\/p>\n<p>Photo: Nasdaq Inc.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>New York\/ Munich \u2014 Morpho\u00adsys, based in Munich, succee\u00added in achie\u00adving the largest IPO of a German biotech company on the Nasdaq in the USA to date and one of the largest share place\u00adments ever in the German biotech sector. The company\u2019s shares were previously only listed in Germany. With the fresh capi\u00adtal, Morpho\u00adsys&nbsp;is&nbsp;[\u2026]<\/p>\n","protected":false},"author":2,"featured_media":42221,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"wp_typography_post_enhancements_disabled":false,"footnotes":""},"categories":[886,1364,1366],"tags":[],"class_list":["post-42213","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-general-en","category-featured-en","category-news-en","news-category-deals-news-en"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v25.1 - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Bravura IPO of Morphosys in the USA - over $200 million raised - FYB Financial Yearbook<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.fyb.de\/en\/bravura-ipo-of-morphosys-in-the-usa-over-200-million-raised\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Bravura IPO of Morphosys in the USA - over $200 million raised - FYB Financial Yearbook\" \/>\n<meta property=\"og:description\" content=\"New York\/ Munich \u2014 Morpho\u00adsys, based in Munich, succee\u00added in achie\u00adving the largest IPO of a German biotech company on the Nasdaq in the USA to date and one of the largest share place\u00adments ever in the German biotech sector. The company\u2019s shares were previously only listed in Germany. With the fresh capi\u00adtal, Morpho\u00adsys is [&hellip;]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.fyb.de\/en\/bravura-ipo-of-morphosys-in-the-usa-over-200-million-raised\/\" \/>\n<meta property=\"og:site_name\" content=\"FYB Financial Yearbook\" \/>\n<meta property=\"article:published_time\" content=\"2018-04-26T19:03:14+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.fyb.de\/wp-content\/uploads\/2018\/04\/a-mo_041918_hires-1.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"600\" \/>\n\t<meta property=\"og:image:height\" content=\"400\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Tatjana Anderer\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Tatjana Anderer\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/www.fyb.de\/en\/bravura-ipo-of-morphosys-in-the-usa-over-200-million-raised\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/www.fyb.de\/en\/bravura-ipo-of-morphosys-in-the-usa-over-200-million-raised\/\"},\"author\":{\"name\":\"Tatjana Anderer\",\"@id\":\"https:\/\/www.fyb.de\/en\/#\/schema\/person\/4308b3086925bc8567ceba3ebd69b4ce\"},\"headline\":\"Bravura IPO of Morphosys in the USA \u2014 over $200 million raised\",\"datePublished\":\"2018-04-26T19:03:14+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/www.fyb.de\/en\/bravura-ipo-of-morphosys-in-the-usa-over-200-million-raised\/\"},\"wordCount\":581,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\/\/www.fyb.de\/en\/#organization\"},\"image\":{\"@id\":\"https:\/\/www.fyb.de\/en\/bravura-ipo-of-morphosys-in-the-usa-over-200-million-raised\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/www.fyb.de\/wp-content\/uploads\/2018\/04\/a-mo_041918_hires-1.jpg\",\"articleSection\":[\"General\",\"Featured\",\"News\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\/\/www.fyb.de\/en\/bravura-ipo-of-morphosys-in-the-usa-over-200-million-raised\/#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/www.fyb.de\/en\/bravura-ipo-of-morphosys-in-the-usa-over-200-million-raised\/\",\"url\":\"https:\/\/www.fyb.de\/en\/bravura-ipo-of-morphosys-in-the-usa-over-200-million-raised\/\",\"name\":\"Bravura IPO of Morphosys in the USA - over $200 million raised - FYB Financial Yearbook\",\"isPartOf\":{\"@id\":\"https:\/\/www.fyb.de\/en\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/www.fyb.de\/en\/bravura-ipo-of-morphosys-in-the-usa-over-200-million-raised\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/www.fyb.de\/en\/bravura-ipo-of-morphosys-in-the-usa-over-200-million-raised\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/www.fyb.de\/wp-content\/uploads\/2018\/04\/a-mo_041918_hires-1.jpg\",\"datePublished\":\"2018-04-26T19:03:14+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/www.fyb.de\/en\/bravura-ipo-of-morphosys-in-the-usa-over-200-million-raised\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/www.fyb.de\/en\/bravura-ipo-of-morphosys-in-the-usa-over-200-million-raised\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/www.fyb.de\/en\/bravura-ipo-of-morphosys-in-the-usa-over-200-million-raised\/#primaryimage\",\"url\":\"https:\/\/www.fyb.de\/wp-content\/uploads\/2018\/04\/a-mo_041918_hires-1.jpg\",\"contentUrl\":\"https:\/\/www.fyb.de\/wp-content\/uploads\/2018\/04\/a-mo_041918_hires-1.jpg\",\"width\":600,\"height\":400},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/www.fyb.de\/en\/bravura-ipo-of-morphosys-in-the-usa-over-200-million-raised\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/www.fyb.de\/en\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Bravura IPO of Morphosys in the USA \u2014 over $200 million raised\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/www.fyb.de\/en\/#website\",\"url\":\"https:\/\/www.fyb.de\/en\/\",\"name\":\"FYB Financial Yearbook\",\"description\":\"For Your Business\",\"publisher\":{\"@id\":\"https:\/\/www.fyb.de\/en\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/www.fyb.de\/en\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/www.fyb.de\/en\/#organization\",\"name\":\"FYB Financial Yearbook\",\"url\":\"https:\/\/www.fyb.de\/en\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/www.fyb.de\/en\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/www.fyb.de\/wp-content\/uploads\/2020\/06\/logo.svg\",\"contentUrl\":\"https:\/\/www.fyb.de\/wp-content\/uploads\/2020\/06\/logo.svg\",\"caption\":\"FYB Financial Yearbook\"},\"image\":{\"@id\":\"https:\/\/www.fyb.de\/en\/#\/schema\/logo\/image\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\/\/www.fyb.de\/en\/#\/schema\/person\/4308b3086925bc8567ceba3ebd69b4ce\",\"name\":\"Tatjana Anderer\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/www.fyb.de\/en\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/11708a5289b743e6290bae8e4109e97efec1cb1ae5c7065f0bfc5c36f28c7757?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/11708a5289b743e6290bae8e4109e97efec1cb1ae5c7065f0bfc5c36f28c7757?s=96&d=mm&r=g\",\"caption\":\"Tatjana Anderer\"},\"description\":\"Gr\u00fcnderin des FYB-Verlag\",\"sameAs\":[\"http:\/\/neu.fyb.de\"],\"url\":\"https:\/\/www.fyb.de\/en\/author\/tanderer\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Bravura IPO of Morphosys in the USA - over $200 million raised - FYB Financial Yearbook","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.fyb.de\/en\/bravura-ipo-of-morphosys-in-the-usa-over-200-million-raised\/","og_locale":"en_US","og_type":"article","og_title":"Bravura IPO of Morphosys in the USA - over $200 million raised - FYB Financial Yearbook","og_description":"New York\/ Munich \u2014 Morpho\u00adsys, based in Munich, succee\u00added in achie\u00adving the largest IPO of a German biotech company on the Nasdaq in the USA to date and one of the largest share place\u00adments ever in the German biotech sector. The company\u2019s shares were previously only listed in Germany. With the fresh capi\u00adtal, Morpho\u00adsys is [&hellip;]","og_url":"https:\/\/www.fyb.de\/en\/bravura-ipo-of-morphosys-in-the-usa-over-200-million-raised\/","og_site_name":"FYB Financial Yearbook","article_published_time":"2018-04-26T19:03:14+00:00","og_image":[{"width":600,"height":400,"url":"https:\/\/www.fyb.de\/wp-content\/uploads\/2018\/04\/a-mo_041918_hires-1.jpg","type":"image\/jpeg"}],"author":"Tatjana Anderer","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Tatjana Anderer","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.fyb.de\/en\/bravura-ipo-of-morphosys-in-the-usa-over-200-million-raised\/#article","isPartOf":{"@id":"https:\/\/www.fyb.de\/en\/bravura-ipo-of-morphosys-in-the-usa-over-200-million-raised\/"},"author":{"name":"Tatjana Anderer","@id":"https:\/\/www.fyb.de\/en\/#\/schema\/person\/4308b3086925bc8567ceba3ebd69b4ce"},"headline":"Bravura IPO of Morphosys in the USA \u2014 over $200 million raised","datePublished":"2018-04-26T19:03:14+00:00","mainEntityOfPage":{"@id":"https:\/\/www.fyb.de\/en\/bravura-ipo-of-morphosys-in-the-usa-over-200-million-raised\/"},"wordCount":581,"commentCount":0,"publisher":{"@id":"https:\/\/www.fyb.de\/en\/#organization"},"image":{"@id":"https:\/\/www.fyb.de\/en\/bravura-ipo-of-morphosys-in-the-usa-over-200-million-raised\/#primaryimage"},"thumbnailUrl":"https:\/\/www.fyb.de\/wp-content\/uploads\/2018\/04\/a-mo_041918_hires-1.jpg","articleSection":["General","Featured","News"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/www.fyb.de\/en\/bravura-ipo-of-morphosys-in-the-usa-over-200-million-raised\/#respond"]}]},{"@type":"WebPage","@id":"https:\/\/www.fyb.de\/en\/bravura-ipo-of-morphosys-in-the-usa-over-200-million-raised\/","url":"https:\/\/www.fyb.de\/en\/bravura-ipo-of-morphosys-in-the-usa-over-200-million-raised\/","name":"Bravura IPO of Morphosys in the USA - over $200 million raised - FYB Financial Yearbook","isPartOf":{"@id":"https:\/\/www.fyb.de\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.fyb.de\/en\/bravura-ipo-of-morphosys-in-the-usa-over-200-million-raised\/#primaryimage"},"image":{"@id":"https:\/\/www.fyb.de\/en\/bravura-ipo-of-morphosys-in-the-usa-over-200-million-raised\/#primaryimage"},"thumbnailUrl":"https:\/\/www.fyb.de\/wp-content\/uploads\/2018\/04\/a-mo_041918_hires-1.jpg","datePublished":"2018-04-26T19:03:14+00:00","breadcrumb":{"@id":"https:\/\/www.fyb.de\/en\/bravura-ipo-of-morphosys-in-the-usa-over-200-million-raised\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.fyb.de\/en\/bravura-ipo-of-morphosys-in-the-usa-over-200-million-raised\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.fyb.de\/en\/bravura-ipo-of-morphosys-in-the-usa-over-200-million-raised\/#primaryimage","url":"https:\/\/www.fyb.de\/wp-content\/uploads\/2018\/04\/a-mo_041918_hires-1.jpg","contentUrl":"https:\/\/www.fyb.de\/wp-content\/uploads\/2018\/04\/a-mo_041918_hires-1.jpg","width":600,"height":400},{"@type":"BreadcrumbList","@id":"https:\/\/www.fyb.de\/en\/bravura-ipo-of-morphosys-in-the-usa-over-200-million-raised\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.fyb.de\/en\/"},{"@type":"ListItem","position":2,"name":"Bravura IPO of Morphosys in the USA \u2014 over $200 million raised"}]},{"@type":"WebSite","@id":"https:\/\/www.fyb.de\/en\/#website","url":"https:\/\/www.fyb.de\/en\/","name":"FYB Financial Yearbook","description":"For Your Business","publisher":{"@id":"https:\/\/www.fyb.de\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.fyb.de\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/www.fyb.de\/en\/#organization","name":"FYB Financial Yearbook","url":"https:\/\/www.fyb.de\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.fyb.de\/en\/#\/schema\/logo\/image\/","url":"https:\/\/www.fyb.de\/wp-content\/uploads\/2020\/06\/logo.svg","contentUrl":"https:\/\/www.fyb.de\/wp-content\/uploads\/2020\/06\/logo.svg","caption":"FYB Financial Yearbook"},"image":{"@id":"https:\/\/www.fyb.de\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/www.fyb.de\/en\/#\/schema\/person\/4308b3086925bc8567ceba3ebd69b4ce","name":"Tatjana Anderer","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.fyb.de\/en\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/11708a5289b743e6290bae8e4109e97efec1cb1ae5c7065f0bfc5c36f28c7757?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/11708a5289b743e6290bae8e4109e97efec1cb1ae5c7065f0bfc5c36f28c7757?s=96&d=mm&r=g","caption":"Tatjana Anderer"},"description":"Gr\u00fcnderin des FYB-Verlag","sameAs":["http:\/\/neu.fyb.de"],"url":"https:\/\/www.fyb.de\/en\/author\/tanderer\/"}]}},"_links":{"self":[{"href":"https:\/\/www.fyb.de\/en\/wp-json\/wp\/v2\/posts\/42213","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.fyb.de\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.fyb.de\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.fyb.de\/en\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.fyb.de\/en\/wp-json\/wp\/v2\/comments?post=42213"}],"version-history":[{"count":0,"href":"https:\/\/www.fyb.de\/en\/wp-json\/wp\/v2\/posts\/42213\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.fyb.de\/en\/wp-json\/wp\/v2\/media\/42221"}],"wp:attachment":[{"href":"https:\/\/www.fyb.de\/en\/wp-json\/wp\/v2\/media?parent=42213"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.fyb.de\/en\/wp-json\/wp\/v2\/categories?post=42213"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.fyb.de\/en\/wp-json\/wp\/v2\/tags?post=42213"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}